Connor Clark & Lunn Investment Management Ltd. Has $682,000 Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Connor Clark & Lunn Investment Management Ltd. lessened its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 28.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,405 shares of the biotechnology company’s stock after selling 16,201 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.28% of Anika Therapeutics worth $682,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in Anika Therapeutics during the 4th quarter valued at $27,000. Quest Partners LLC lifted its holdings in Anika Therapeutics by 115.8% during the 3rd quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 3,705 shares during the last quarter. Atria Investments Inc acquired a new stake in Anika Therapeutics during the 3rd quarter valued at $218,000. Los Angeles Capital Management LLC lifted its holdings in Anika Therapeutics by 9.1% during the 4th quarter. Los Angeles Capital Management LLC now owns 11,700 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 980 shares during the last quarter. Finally, HighTower Advisors LLC lifted its holdings in Anika Therapeutics by 11.3% during the 3rd quarter. HighTower Advisors LLC now owns 15,883 shares of the biotechnology company’s stock valued at $387,000 after purchasing an additional 1,615 shares during the last quarter. Institutional investors and hedge funds own 91.53% of the company’s stock.

Anika Therapeutics Stock Performance

Shares of NASDAQ ANIK opened at $15.42 on Friday. Anika Therapeutics, Inc. has a 52 week low of $14.95 and a 52 week high of $29.12. The stock has a market capitalization of $225.84 million, a P/E ratio of -2.32 and a beta of 0.95. The stock’s fifty day moving average is $16.90 and its 200 day moving average is $19.21.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.13). Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. The company had revenue of $30.60 million during the quarter, compared to the consensus estimate of $29.00 million. Equities research analysts forecast that Anika Therapeutics, Inc. will post -0.84 earnings per share for the current year.

Analysts Set New Price Targets

ANIK has been the topic of several recent research reports. StockNews.com upgraded Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Barrington Research lowered their price objective on Anika Therapeutics from $25.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, March 13th.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.